Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026

Same author

The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Cell·2026

Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026

Same author

Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot study.

Nature communications·2026

Same author

Labor and Disability: A Nation-Wide Analysis of Pregnancy Outcomes after Spinal Cord Injury.

Journal of neurotrauma·2026

Same author

A phase 2 study of niraparib concomitant with tumor treating fields in patients with recurrent grade 4 glioma.

Neuro-oncology advances·2026

Search research articles

Related Experiment Video

Updated: Jul 16, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Optimizing CAR-T Therapy for Glioblastoma.

Oliver Y Tang¹, Zev A Binder², Donald M O'Rourke²

¹Warren Alpert Medical School, Brown University, Providence, RI, 02903, USA.

Molecular Diagnosis & Therapy

|September 12, 2023

Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for glioblastoma treatment but faces challenges. Research focuses on new targets, improved CAR constructs, and combination therapies to enhance efficacy against this brain tumor.

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jul 16, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Area of Science:

Neuro-oncology
Immunotherapy
Cellular Therapy

Background:

Glioblastoma is a fatal brain cancer with limited treatment options.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized blood cancer treatment but struggles with solid tumors like glioblastoma.

Approach:

Reviewing strategies to overcome glioblastoma's challenges for CAR T-cell therapy.
Exploring new antigen targets and advanced CAR T-cell designs.
Investigating combination therapies and immune-evading tactics.

Key Points:

Developing novel CAR T-cell strategies for glioblastoma is crucial.
Identifying new tumor antigens and engineering better CAR constructs are key.
Overcoming the tumor microenvironment and T-cell dysfunction are critical.

Conclusions:

Optimizing CAR T-cell therapy requires innovative approaches.
Future strategies involve targeting, engineering, and combining therapies for glioblastoma.
Addressing challenges in the tumor microenvironment is essential for clinical success.